These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19650745)

  • 1. The role of sulfamide derivatives in medicinal chemistry: a patent review (2006-2008).
    Reitz AB; Smith GR; Parker MH
    Expert Opin Ther Pat; 2009 Oct; 19(10):1449-53. PubMed ID: 19650745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of sulfamides as enzyme inhibitors.
    Winum JY; Scozzafava A; Montero JL; Supuran CT
    Med Res Rev; 2006 Nov; 26(6):767-92. PubMed ID: 16710859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sulfamide motif in the design of enzyme inhibitors.
    Winum JY; Scozzafava A; Montero JL; Supuran CT
    Expert Opin Ther Pat; 2006 Jan; 16(1):27-47. PubMed ID: 20141508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary and tertiary sulfonamides: a patent review (2008 - 2012).
    Scozzafava A; Carta F; Supuran CT
    Expert Opin Ther Pat; 2013 Feb; 23(2):203-13. PubMed ID: 23148584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements.
    Klinger AL; McComsey DF; Smith-Swintosky V; Shank RP; Maryanoff BE
    J Med Chem; 2006 Jun; 49(12):3496-500. PubMed ID: 16759092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.
    Ivachtchenko AV; Ivanenkov YA
    Expert Opin Ther Pat; 2012 Aug; 22(8):917-64. PubMed ID: 22816965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting key example compounds in competitors' patent applications using structural information alone.
    Hattori K; Wakabayashi H; Tamaki K
    J Chem Inf Model; 2008 Jan; 48(1):135-42. PubMed ID: 18177028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazole-based sulfonamide and sulfamides as potent inhibitors of mammalian 15-lipoxygenase.
    Ngu K; Weinstein DS; Liu W; Langevine C; Combs DW; Zhuang S; Chen X; Madsen CS; Harper TW; Ahmad S; Robl JA
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4141-5. PubMed ID: 21696952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in medicinal chemistry of sulfonamides. Rational design as anti-tumoral, anti-bacterial and anti-inflammatory agents.
    Shah SS; Rivera G; Ashfaq M
    Mini Rev Med Chem; 2013 Jan; 13(1):70-86. PubMed ID: 22625411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sulfonamide group as a structural alert: A distorted story?
    Smith DA; Jones RM
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):72-9. PubMed ID: 18175269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR design of novel antiepileptic sulfamides.
    Gavernet L; Dominguez Cabrera MJ; Bruno-Blanch LE; Estiú GL
    Bioorg Med Chem; 2007 Feb; 15(3):1556-67. PubMed ID: 17158052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonimidamides in Medicinal and Agricultural Chemistry.
    Chinthakindi PK; Naicker T; Thota N; Govender T; Kruger HG; Arvidsson PI
    Angew Chem Int Ed Engl; 2017 Apr; 56(15):4100-4109. PubMed ID: 27958674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.
    Manku S; Allan M; Nguyen N; Ajamian A; Rodrigue J; Therrien E; Wang J; Guo T; Rahil J; Petschner AJ; Nicolescu A; Lefebvre S; Li Z; Fournel M; Besterman JM; Déziel R; Wahhab A
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1866-70. PubMed ID: 19272776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety.
    Ghorab MM; Ragab FA; Hamed MM
    Eur J Med Chem; 2009 Oct; 44(10):4211-7. PubMed ID: 19540022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of sulfur-containing motifs in drug design and discovery.
    Mustafa M; Winum JY
    Expert Opin Drug Discov; 2022 May; 17(5):501-512. PubMed ID: 35193437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial agents: patent highlights January to June 2002.
    Phillips OA; Matowe WC
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1701-11. PubMed ID: 12528302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides.
    Zimmerman S; Innocenti A; Casini A; Ferry JG; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6001-6. PubMed ID: 15546717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico identification of bioisosteric functional groups.
    Ertl P
    Curr Opin Drug Discov Devel; 2007 May; 10(3):281-8. PubMed ID: 17554854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfamide as Zinc Binding Motif in Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa).
    Halland N; Czech J; Czechtizky W; Evers A; Follmann M; Kohlmann M; Schreuder HA; Kallus C
    J Med Chem; 2016 Oct; 59(20):9567-9573. PubMed ID: 27749053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.